WASHINGTON -- The U.S. Food and Drug Administration said Friday it is considering a proposal by Amgen Inc. and Johnson & Johnson to modify labels on their anti-anemia drugs to provide a target hemoglobin range, or a measure of red blood cells, in kidney-failure patients.
